Kalbitor Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kalbitor market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as the increasing prevalence of hereditary angioedema (HAE), greater awareness of HAE among healthcare providers, the expansion of healthcare infrastructure in developed regions, increased government support for rare disease treatments, and the higher adoption of biologic therapies.

Market growth during the forecast period can be driven by increased investments in HAE research and development, expanded patient access to advanced treatments, rising use of telemedicine for managing HAE, growing prevalence of genetic testing for early diagnosis, and the expansion of the healthcare market in the Asia-Pacific region. Key trends during the forecast period include the growth of personalized medicine approaches for HAE, increasing adoption of gene-editing technologies, a focus on patient-centric treatment strategies, the development of single-dose HAE therapies, and strategic mergers and acquisitions within the rare disease sector.

The increasing prevalence of hereditary angioedema (HAE) is anticipated to fuel the growth of the kalbitor market in the future. Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of severe swelling in various body parts, including the extremities, gastrointestinal tract, and airway. The rising prevalence of HAE is primarily due to enhanced awareness, better diagnostic capabilities, and improved recognition among healthcare providers. Kalbitor (ecallantide), a plasma kallikrein inhibitor, plays a crucial role in managing acute HAE attacks, improving patient outcomes and overall quality of life. For example, in June 2022, Rare Disease Advisor, a US-based online resource for healthcare professionals, reported that HAE affects about 1 in 50,000 individuals globally, with prevalence estimates ranging from 1,10,000 to 1,150,000. In the US, HAE episodes contribute to 15,000 to 30,000 emergency department visits annually. Thus, the increasing prevalence of hereditary angioedema (HAE) is driving the kalbitor market.

The growing aging population is expected to boost the kalbitor market moving forward. The aging population refers to individuals aged 65 and older, a trend driven by increased life expectancy and declining birth rates. This demographic shift is supported by advancements in healthcare, medical technology, and improved living conditions. Kalbitor is particularly beneficial for the aging population with hereditary angioedema (HAE), providing a targeted treatment for acute swelling attacks and minimizing risks associated with aging. For instance, in January 2024, the Population Reference Bureau (PRB), a US-based nonprofit research organization, reported that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, reflecting a 47% rise. Their share of the total population is expected to grow from 17% to 23%. Therefore, the aging population is contributing to the growth of the kalbitor market.

The rise in healthcare expenditure is also expected to drive the kalbitor market. Healthcare expenditure refers to the total spending on healthcare goods and services, including personal health care, preventive services, and public health initiatives aimed at improving health outcomes over a specific period. This increase in healthcare spending is attributed to factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment models, and higher demand for healthcare services. Rising healthcare expenditure enables greater access to specialized treatments for rare diseases such as hereditary angioedema (HAE), allowing healthcare systems to allocate resources for innovative therapies, patient management, and comprehensive care. For example, in May 2024, a report from the Office for National Statistics, a UK-based government agency, highlighted a 5.6% increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth in 2022. Thus, rising healthcare expenditure is driving the kalbitor market.

The key company operating in the kalbitor market is Takeda Pharmaceutical Company.

North America was the largest region in the kalbitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kalbitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kalbitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kalbitor (ecallantide) is a recombinant protein that effectively inhibits plasma kallikrein, an enzyme responsible for producing bradykinin, a key mediator of inflammation and swelling. It is primarily used for treating acute attacks of hereditary angioedema (HAE), a rare genetic disorder marked by sudden and severe swelling in different areas of the body.

The main indications for kalbitor are the treatment of acute attacks of hereditary angioedema (HAE) and the prophylaxis of HAE. Treating acute attacks of HAE involves the timely use of targeted therapies such as C1 inhibitors, kallikrein inhibitors, or bradykinin receptor antagonists to reduce swelling and prevent complications. The available formulations include injectable versions and lyophilized powders for reconstitution. Kalbitor is used by a range of patient groups, including pediatric, adult, and geriatric patients. It is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. The end users of Kalbitor include hospitals, specialty clinics, home healthcare providers, and emergency departments.

The kalbitor market research report is one of a series of new reports that provides kalbitor market statistics, including kalbitor industry global market size, regional shares, competitors with a kalbitor market share, detailed kalbitor market segments, market trends and opportunities, and any further data you may need to thrive in the kalbitor industry. This kalbitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kalbitor market consists of sales of kalbitor (ecallantide) for the treatment of hereditary angioedema (HAE). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.